Reports Q1 revenue $68.788M, consensus $71.68M. "The strong new patient growth in the first quarter, building on our large patient base with ORLADEYO, positions us very well to achieve our expectations for 2023, and advances us on a trajectory to peak sales of $1 billion. This growing revenue stream, alongside our robust balance sheet, has dramatically reduced our reliance on the capital markets as we drive value with continued commercial execution and disciplined investment in our pipeline," said Jon Stonehouse, president and chief executive officer of BioCryst.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCRX:
- BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
- BioCryst presents new data from APeX-S clinical trial evaluating ORDALEYO
- BioCryst price target lowered to $10 from $13 at Evercore ISI
- BioCryst to Report First Quarter 2023 Financial Results on May 3
- BioCryst announces $450M financing commitment from Pharmakon